Voloridge Investment Management’s UroGen Pharma URGN Stock Holding History

Voloridge Investment Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.09M	Sell	111,141 -119,489	-52%	-$3.24M	0.02%	570
2026 Q1	$4.15M	Sell	230,630 -204,860	-47%	-$4.11M	0.02%	709
2025 Q4	$10.2M	Sell	435,490 -251,985	-37%	-$5.47M	0.04%	574
2025 Q3	$13.7M	Buy	+687,475	New	+$12.3M	0.05%	451
2019 Q2	–	Sell	-5,970	Closed	-$221K	–	1090
2019 Q1	$221K	Buy	+5,970	New	+$250K	0.01%	876

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Voloridge Investment Management's URGN Position: Q2 2026 in Review

Voloridge Investment Management reduced its UroGen Pharma (URGN) stake by 52% in Q2 2026, selling an estimated $3.24M and leaving 111,141 shares worth $4.09M. The position accounts for 0.02% of the portfolio, ranked #570.

Voloridge Investment Management first reported a position in URGN in Q1 2019 and has held it in 5 quarters since. The position peaked at $13.7M in Q3 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Voloridge Investment Management held 111,141 shares of UroGen Pharma worth $4.09M as of Q2 2026.
Voloridge Investment Management sold 119,489 UroGen Pharma shares in Q2 2026, an estimated $3.24M.
UroGen Pharma made up 0.02% of Voloridge Investment Management's portfolio in Q2 2026, its #570 holding.
Voloridge Investment Management first reported a position in UroGen Pharma in Q1 2019 and has held it in 5 quarters since.
Voloridge Investment Management's UroGen Pharma position peaked at $13.7M in Q3 2025.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.